前列腺是臨床上重要的男性附屬生殖腺，對精液產生至關重要。前列腺癌現時在香港男性癌症年度發病率中排名第3位，在男性癌症相關死亡中排名第5位，每100,000人約有10.9宗死亡。其發病率正迅速上升，過去10年幾乎增加三倍。
適應症：Prostate Cancer
收案條件
納入條件
- For non prostate cancer group
- Male subject with age 45 or above
- No clinical evidence of PCa, serum PSA \<4 ng/dl and normal digital rectal examination.
- For prostate cancer group
- Male subject with age 45 or above
- Clinically diagnosed to have localized PCa and planned for radical prostatectomy
- No prior systemic therapy for PCa used, including hormonal or chemotherapy.
排除條件
- History of medications usage that can affect serum PSA levels within 6 months of study enrolment.
- History of active urinary tract infection within 1 month of study enrolment.
- History of invasive prostate / bladder treatments within 6 months of study enrolment.
- History of concurrent renal/bladder cancer within 6 months of study enrolment.
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年11月5日。